MiNK Therapeutics (NASDAQ: INKT) reported a net loss of $3.1 million, or $0.62 per share, for the second quarter ended ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE